Artiva Biotherapeutics, Inc.
For the period ended Dec 31, 2025. Filed Mar 10, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 9B. Other Information
Trading Arrangements
During the fiscal quarter ended December 31, 2025, our directors and officers (as defined in Rule 16a-1(f) under the Exchange Act) adopted or terminated the contracts, instructions or written plans for the purchase or sale of the Company’s securities set forth in the table below:
| Type of Trading Arrangement | |||||
|---|---|---|---|---|---|
| Name and Position · Action · Adoption / Termination Date · Rule 10b5-1* · Non-Rule 10b5-1** · Total Shares of Common Stock to be Sold · Expiration Date | |||||
| Fred Aslan, M.D. (President, Chief Executive Officer and Director) | Termination1 | December 29, 2025 | X | 471,558 | December 31, 2026 |
| Jennifer Bush (Chief Operating Officer, Chief Legal Officer and Compliance Officer) | Termination2 | December 22, 2025 | X | 28,000 | May 31, 2026 |
| Christopher Horan (Chief Technical Operations Officer) | Termination3 | December 15, 2025 | X | 44,200 | April 15, 2026 |
| Heather Raymon (Senior Vice President of Research and Early Development) | Termination4 | December 15, 2025 | X | 25,434 | April 15, 2026 |
| * Contract, instruction or written plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act. | |||||
| ** “Non-Rule 10b5-1 trading arrangement” as defined in Item 408(c) of Regulation S-K under the Exchange Act. | |||||
1 Represents the termination of a written plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) adopted on July 23, 2024.2 Represents the termination of a written plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) adopted on July 23, 2024.3 Represents the termination of a written plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) adopted on July 23, 2024.4 Represents the termination of a written plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) adopted on July 23, 2024.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.